Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: A retrospective study in UK primary care

International Journal of Clinical Practice

Volumn 69, Issue 3, 2015, Pages 281-291

  Nyeland, M E ^a   Ploug, U J ^a   Richards, A ^a   Garcia Alvarez, L ^b   Demuth, D ^b   Muthutantri, A ^b   Skovgaard, R ^a   Evans, M ^c  

^a NOVO NORDISK A S   (Denmark)

^b IQVIA   (United States)

^c LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BODY MASS; CHARLSON COMORBIDITY INDEX; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNITED KINGDOM; WEIGHT REDUCTION; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PRIMARY HEALTH CARE; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

EID: 84923372349     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12575     Document Type: Article

References (34)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
2. WHO. WHO/NCD/NCS/99.2: definition, diagnosis and classification of diabetes mellitus and its complications, 1999.
3. Diabetes UK. Diabetes in the UK 2012, Key statistics on diabetes. 2012.
4. NHS 2013. Statistics on Obesity, Physical Activity and Diet: England, 2013. Leeds, United Kingdom: Health and Social Care Information Centre, Lifestyles Statistics, 2013.
5. Scottish Government. The Scottish Health Survey 2011, Volume 1: Main Report, 2012.
6. Welsh Assembly. The Welsh Health Survey, 2011, 2012.
7. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006; 26: 968-76.
8. Sethi BK, Viswanathan V, Kumar A, Chatterjee S, Chandalia HB,. Liraglutide in clinical practice: insights from LEAD programme. Suppl JAPI 2010; 58: 18-22.
9. Astrup A, Finer N,. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000; 1: 57-9.
10. NICE. Type 2 diabetes: The management of type 2 diabetes. Clinical guideline 66, 2008. http://www.nice.org.uk/nicemedia/pdf/cg66niceguideline.pdf (accessed 8 November 2013).
11. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-59.
12. NICE. The management of type 2 diabetes. Clinical guideline 87, 2009. http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf (accessed 8 November 2013).
13. NICE. Liraglutide for the treatment of type 2 diabetes. Technology appraisal guidance 203. 2010. http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdf (accessed 8 November 2013).
14. Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
15. Neumiller JJ,. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009; 49 (Suppl. 1): S16-29.
16. Grossman S,. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide. Pharmacotherapy 2009; 29: 25S-32S.
17. Meece J,. Pharmacokinetics and pharmacodynamics of liraglutide, a long-Acting, potent glucagon-like peptide-1 analog. Pharmacotherapy 2009; 29: 33S-42S.
18. Baggio LL, Drucker DJ,. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
19. McGill JB,. Liraglutide: effects beyond glycaemic control in diabetes treatment. Int J Clin Pract 2010; 64 (Suppl. 167): 28-34.
20. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
21. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-81.
22. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-78.
23. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
24. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-55.
25. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-30.
26. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65: 397-407.
27. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-56.
28. Evans M, McEwan P, O'Shea R, George L,. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther 2013; 4: 27-40.
29. Clinical Practice Research Datalink (CPRD). http://www.cprd.com/intro.asp (accessed 22 November 2013).
30. MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010; 33: 1213-8.
31. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2013. Diabetes Care 2013; 36 (Suppl. 1): S4-10.
32. Khan NF, Perera R, Harper S, Rose PW,. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010; 11: 1.
33. Martinez L, Gourdy P, Eschwege E, et al. Baseline observations, characteristics of type 2 diabetes patients initiating liraglutide from the EVIDENCE: a prospective, 2-year follow-up, post-marketing study. 73rd Scientific Sessions (Abstract). Diabetes 2013; 62: A662.
34. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013; 15: 42-54.